CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE: The level of the degradation product Benzaldehyde may be out of specification in the affected lots.
Brand(s)
Last updated
Summary
Product
CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE
Issue
Health products - Product quality
What to do
Consult your healthcare provider for any health concerns.
Audience
Healthcare
Industry
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot Number |
|---|---|---|---|---|---|
Omega Laboratories Limited |
Cisatracurium Besylate Injection USP Multidose |
DIN 02408813 |
Solution |
Cisatracurium (Cisatracurium besilate) 2 mg/mL |
B5C646A, |
Issue
The level of the degradation product Benzaldehyde may be out of specification in the affected lots.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Juno Pharma Canada Inc.
(Omega Laboratories Limited)
11177 Rue Hamon, Montreal, QC, Canada H3M 3E4
Published by
Health Canada
Audience
Healthcare
Industry
Recall class
Type III
Recall date
Identification number
RA-82501
Get notified
Receive emails about new and updated recall and safety alerts.